Clinical TrialsSearch results
Number of results: 553
Recruiting
- Efficacy of Physical Activity Intervention in Preventing Hospital-acquired disability in Elderly Patients with Heart Failure
- Heart failure
- Yosuke Takahashi
- 2023-04-22
Other
- Switch study between MD-0901 formulations in Patients with Ulcerative Colitis in Remission Phase
- Ulcerative colitis in remission phase
- Kusaba Keiko
- 2023-04-16
Recruiting
- MK-3475 Monotherapy versus Sacituzumab Govitecan in Combination with MK-3475 for PD-L1 TPS >=50% Metastatic NSCLC
- NSCLC
- Koh Yasuhiro
- 2023-04-16
Recruiting
- Caplacizumab and immunosuppressive therapy without firstline therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura
- Thrombotic Thrombocytopenic Purpura
- Tanaka Tomoyuki
- 2023-04-16
Recruiting
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
- Generalized Myasthenia Gravis
- Kanemoto Koji
- 2023-04-13
Other
- Evaluation of the Safety and Efficacy of AL3818 in Subjects with Recurrent or Metastatic Ovarian, Fallopian, and Primary Peritoneal Carcinoma
- Recurrent or metastatic platinum refractory, resistant ovarian, fallopian, primary peritoneal cancer
- Kitano Tina
- 2023-04-07
Other
- Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in East Asian participants with overweight or obesity(NN9838-4762)
- Obesity
- Sudo Yuki
- 2023-03-26
Other
- Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes
- overweight or obesity and type 2 diabetes
- Ishikawa Wataru
- 2023-03-02
Recruiting
- The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease
- Obesity and cardiovascular disease
- Ryoma Akihito Hirose
- 2023-03-02
Recruiting
- A study to investigate the efficacy and safety of dupilumab therapy compared with placebo in participants aged >=18 years with moderately to severely active ulcerative colitis with an eosinophilic phenotype
- Colitis ulcerative
- Tanaka Tomoyuki
- 2023-02-27